Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Gene Patenting Lawsuit Against Myriad Genetics

…the United States Supreme Court made history when it unanimously ruled that the Myriad Genetics’ patents on the BRCA1 and BRCA2 genes were invalid.

FORCE agrees with the Court that genes – as products of nature – should not be patented. FORCE filed an amicus brief in support of the ACLU and testified to the Patent and Trademark Office about the burden that gene patents place on members of our community.

Specifically, the Court stated that “In this case … Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.”

So what does this mean for our community?

  • It paves the way for other companies to test for mutations on these genes and in fact companies have already stepped forward to offer BRCA testing at a lower cost than Myriad’s test. FORCE will be compiling a list of labs offering BRCA testing.
  • Patients will now have the opportunity to get a second opinion to confirm their genetic test results prior to making life altering preventive surgery decisions.
  • More women (and men) will have access to potentially life-saving genetic information because competition has lowered the cost of these genetic tests.
  • No single company will be able to prevent others from conducting testing and research on the BRCA genes.

We applaud this decision and believe that one barrier to personalized medicine, testing, hereditary cancer research, and better prevention and treatment options has been surmounted with this ruling.

FORCE recommends people consult with an expert in cancer genetics before and after genetic testing for cancer risk. You can visit our website to learn more about genetic counseling and testing, to find a genetics expert in your area, or to learn about risk management options.

With help from a team of research advocates, OCNA compiled a report on ovarian cancer research presented at the 2013 ASCO meeting

…the United States Supreme Court made history when it unanimously ruled that the Myriad Genetics’ patents on the BRCA1 and BRCA2 genes were invalid.

FORCE agrees with the Court that genes – as products of nature – should not be patented. FORCE filed an amicus brief in support of the ACLU and testified to the Patent and Trademark Office about the burden that gene patents place on members of our community.

Specifically, the Court stated that “In this case … Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.”

So what does this mean for our community?

  • It paves the way for other companies to test for mutations on these genes and in fact companies have already stepped forward to offer BRCA testing at a lower cost than Myriad’s test. FORCE will be compiling a list of labs offering BRCA testing.
  • Patients will now have the opportunity to get a second opinion to confirm their genetic test results prior to making life altering preventive surgery decisions.
  • More women (and men) will have access to potentially life-saving genetic information because competition has lowered the cost of these genetic tests.
  • No single company will be able to prevent others from conducting testing and research on the BRCA genes.

We applaud this decision and believe that one barrier to personalized medicine, testing, hereditary cancer research, and better prevention and treatment options has been surmounted with this ruling.

FORCE recommends people consult with an expert in cancer genetics before and after genetic testing for cancer risk. You can visit our website to learn more about genetic counseling and testing, to find a genetics expert in your area, or to learn about risk management options.

With help from a team of research advocates, OCNA compiled a report on ovarian cancer research presented at the 2013 ASCO meeting

…the United States Supreme Court made history when it unanimously ruled that the Myriad Genetics’ patents on the BRCA1 and BRCA2 genes were invalid.

FORCE agrees with the Court that genes – as products of nature – should not be patented. FORCE filed an amicus brief in support of the ACLU and testified to the Patent and Trademark Office about the burden that gene patents place on members of our community.

Specifically, the Court stated that “In this case … Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.”

So what does this mean for our community?

  • It paves the way for other companies to test for mutations on these genes and in fact companies have already stepped forward to offer BRCA testing at a lower cost than Myriad’s test. FORCE will be compiling a list of labs offering BRCA testing.
  • Patients will now have the opportunity to get a second opinion to confirm their genetic test results prior to making life altering preventive surgery decisions.
  • More women (and men) will have access to potentially life-saving genetic information because competition has lowered the cost of these genetic tests.
  • No single company will be able to prevent others from conducting testing and research on the BRCA genes.

We applaud this decision and believe that one barrier to personalized medicine, testing, hereditary cancer research, and better prevention and treatment options has been surmounted with this ruling.

FORCE recommends people consult with an expert in cancer genetics before and after genetic testing for cancer risk. You can visit our website to learn more about genetic counseling and testing, to find a genetics expert in your area, or to learn about risk management options.

With help from a team of research advocates, OCNA compiled a report on ovarian cancer research presented at the 2013 ASCO meeting

http://www.facingourrisk.org/advocacy/current_action/gene_patenting.php

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada

%d bloggers like this: